News - Alphyn

News and Events

Press Releases

Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis

December 10, 2024

Alphyn Biologics Announces Peer-Reviewed Paper Published in Journal of Drugs in Dermatology

November 1, 2024

Alphyn to Present Poster on Zabalafin Hydrogel Clinical Results at European Academy of Dermatology and Venereology Congress 2024

August 27, 2024

Alphyn Receives Notice of Claims Allowance for U.S. Patent Covering Zabalafin Hydrogel

August 21, 2024

Alphyn Announces Positive Results from Second Cohort of Phase 2a Clinical Trial in Atopic Dermatitis

March 7, 2024

Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection

July 14, 2023

Alphyn Biologics Presents New Data from Phase 2a Trial Showing Significant Improvement of Mild-to-Moderate Atopic Dermatitis

July 10, 2023

Alphyn Biologics Reports Positive Pediatric Results from Phase 2a Atopic Dermatitis Trial

May 4, 2023

Alphyn Biologics Presents Pediatric Data from Atopic Dermatitis Trial at European Society for Pediatric Dermatology Congress

April 27, 2023

Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment

January 4, 2023

Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis

November 15, 2022

Alphyn Biologics Announces Enrollment Passes Halfway Point in Phase2a Clinical Trial of Mild-to-Moderate Atopic Dermatitis Treatment

October 18, 2022

Alphyn Biologics Closes $3.3 Million Series A Financing to Advance Breakthrough Atopic Dermatitis Treatment

September 15, 2022

Clinical Trials Arena: Alphyn prepares for two global trials in atopic dermatitis

July 26, 2023

Healio: Interim results show AB-101a significantly controls atopic dermatitis skin bacteria

July 17, 2023

Dermatology Times: Alphyn Biologics Shares Positive Interim Results of Phase 2a Trial for AD With Secondary Bacterial Infection

July 14, 2023

Healio: AB-101a rapidly reduces itch in patients aged as young as 2 years with atopic dermatitis

July 14, 2023

Dermatology Times: Topical Therapeutic Shows Significant Improvement in Mild-to-Moderate Atopic Dermatitis

July 11, 2023

VIDEO: Alphyn Biologics’ Atopic Dermatitis Candidate Shows Positive Early Results

March 21, 2023

Empowered Patient Podcast: Treating Atopic Dermatitis with Neal Koller, CEO, Alphyn Biologics

February 27, 2023

International Society of Atopic Dermatitis Poster Presentation: Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin

October 26, 2024

2024 European Association of Dermatology and Venerology (EADV) Poster Presentation: Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin Hydrogel

September 28, 2024

Society for Pediatric Dermatology Poster Presentation: First-in-Human Phase 2 Trial of Zabalafin Hydrogel (AB-101a) – Itch and Quality of Life Pediatric Results

July 8, 2024

Masters of Pediatric Dermatology Symposium Poster Presentation: First in Human Phase 2 Trial of Zabalafin (AB-101) – Interim Results

February 8, 2024

Society for Pediatric Dermatology Poster Presentation: Phase 2a Trial of Topical Therapeutic for Mild, Moderate, and Severe Atopic Dermatitis

July 13, 2023

World Congress of Dermatology Poster Presentation: Phase 2a Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis

July 6, 2023

European Society for Pediatric Dermatology Poster Presentation: Pediatric Data from Phase 2a Trial of AB-101a for Mild-to-Moderate Atopic Dermatitis

May 4, 2023

Masters of Pediatric Dermatology

February 6 – 7, Miami Beach, FL

Poster presentation

Past Events

The Nexus Healthcare Event

January 14 – 16, 2025, South San Francisco, CA

Corporate presentation

RESI JPM 2025 (Redefining Early Stage Investments)

January 14, 2025, San Francisco, CA

Corporate presentation; Innovators Pitch Challenge

Biotech Showcase 2025

January 13 – 15, 2025, San Francisco, CA

Corporate presentation

BIO-Europe

November 4 – 6, 2024, Stockholm, Sweden

Corporate presentation

BIO Investor Forum

October 15 – 16, 2024, San Francisco, CA

Corporate presentation

European Academy of Dermatology and Venereology (EADV) Congress 2024

September 25 – 28, 2024, Amsterdam, The Netherlands

Poster presentation

MedInvest Biotech & Pharma

September 18 – 19, 2024, New York, NY

Corporate presentation

New York Venture Summit

September 6 – 7, 2024, New York, NY

Corporate presentation

Press Releases

In the News

Clinical Presentations

Upcoming Events

Past Events